Events Archives - Page 71 of 128

2 minute read

Elevation Oncology Highlights Clinical Data For SYSA1801 To Be Presented By Partner CSPC Pharmaceutical Group Limited At ASCO 2023

April 27, 6:58 AM

Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet

ELEV

1 minute read

Leap Therapeutics To Present Updated Data From Part A Of The DisTinGuish Study Of DKN-01 Plus Tislelizumab And Chemotherapy In Gastric Cancer Patients At The 2023 ASCO Annual Meeting

By Happy Mohamed

April 27, 6:57 AM

Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new long-term follow-up data

LPTX

1 minute read

eFFECTOR To Present Updated Clinical Data From Phase 2 Expansion Cohorts For Zotatifin In Patients With ER+ Metastatic Breast Cancer At ASCO 2023 Annual Meeting

By Happy Mohamed

April 27, 6:56 AM

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced a poster highlighting results from

EFTR

1 minute read

Oncolytics Biotech Announces Upcoming Oral Presentation On Randomized BRACELET-1 Trial In HR+/HER2- Metastatic Breast Cancer At The ASCO Annual Meeting

By Happy Mohamed

April 26, 10:45 AM

Oral presentation on BRACELET-1 to take place on June 3, 2023

ONCY

2 minute read

Zai Lab Announces Presentation Of Results Of The LUNAR Phase 3 Clinical Trial In Non-Small Cell Lung Cancer At 2023 American Society Of Clinical Oncology Annual Meeting

By Happy Mohamed

April 26, 10:26 AM

Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)))) today announced that the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023

ZLAB

3 minute read

Gracell Biotechnologies To Present Updated Clinical Data On BCMA/CD19 Dual-Targeting FasTCAR-T GC012F At 2023 ASCO Annual Meeting

By Happy Mohamed

April 26, 10:26 AM

Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell

GRCL

2 minute read

Cullinan Oncology To Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, In Patients With Advanced Solid Tumors At ASCO 2023

By Happy Mohamed

April 26, 10:13 AM

Cullinan Oncology, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that the first clinical data from its Phase 1 clinical study of

CGEM

2 minute read

Immutep Announces Presentation Of New TACTI-002 Data At The 2023 ASCO Annual Meeting

By Happy Mohamed

April 26, 10:08 AM

Final results from Part C of the Phase II TACTI-002 trial in 2nd line head and neck squamous cell carcinoma patients to be presented SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE)

IMMP

2 minute read

Allogene Therapeutics Announces Presentation Of Phase 1 Data From The ALLO-501/501A Trials In Large B Cell Lymphoma At The American Society Of Clinical Oncology Annual Meeting

By Happy Mohamed

April 26, 10:07 AM

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced it will present updated data

ALLO

2 minute read

Theseus Pharmaceuticals Initial Dose Escalation Results From Ongoing Phase 1/2 Trial Of THE-630 Accepted For Online Publication At 2023 ASCO Annual Meeting

By Happy Mohamed

April 26, 10:07 AM

-- Company to host virtual investor event to review updated data on May 25, 2023 at 5:30pm ET -- CAMBRIDGE, Mass., April 26, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX)

THRX